Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Monday, March 23, 2026 1 min read
Key Takeaway: Gilead Sciences has announced its acquisition of Ouro Medicines, a company specializing in T cell engager therapies for autoimmune diseases. This strategic move includes the addition of OM336, a clinical-stage BCMAxCD3 T cell engager, to Gilead's inflammation portfolio. The acquisition aims to enhance Gilead's capabilities in treating autoimmune conditions.
Market Sentiment Analysis
POSITIVE FACTORS
Gilead expands its portfolio with the acquisition of Ouro Medicines.
OM336 is a promising clinical-stage therapy for autoimmune diseases.
The acquisition strengthens Gilead's position in the inflammation market.
Full Press Release Details
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously admi
Frequently Asked Questions
What is the purpose of Gilead's acquisition of Ouro Medicines?
The acquisition aims to enhance Gilead's T cell engager program for autoimmune diseases.
What is OM336?
OM336 is a clinical-stage BCMAxCD3 T cell engager developed by Ouro Medicines.
How does OM336 work?
OM336 is designed to enable rapid and deep B cell depletion through subcutaneous administration.
What does this acquisition mean for Gilead's portfolio?
This acquisition strengthens Gilead's inflammation portfolio and expands its treatment options.